Louise Birkedal Glenthøj

List of Publications by Year
in descending order

31 papers	691 citations	623734 14 h-index	610901 24 g-index
31 all docs	31 docs citations	31 times ranked	818 citing authors

#	Article	IF	Citations
1	EPA guidance on assessment of negative symptoms in schizophrenia. European Psychiatry, 2021, 64, e23.	0.2	94
2	Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis. JAMA Psychiatry, 2021, 78, 753.	11.0	74
3	EPA guidance on treatment of negative symptoms in schizophrenia. European Psychiatry, 2021, 64, e21.	0.2	70
4	The effect of cognitive remediation in individuals at ultra-high risk for psychosis: a systematic review. NPJ Schizophrenia, 2017, 3, 20.	3.6	62
5	Social cognition in patients at ultra-high risk for psychosis: What is the relation to social skills and functioning?. Schizophrenia Research: Cognition, 2016, 5, 21-27.	1.3	46
6	The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial. Trials, 2015, 16, 25.	1.6	40
7	Cerebral glutamate and GABA levels in high-risk of psychosis states: A focused review and meta-analysis of 1H-MRS studies. Schizophrenia Research, 2020, 215, 38-48.	2.0	36
8	Negative symptoms mediate the relationship between neurocognition and function in individuals at ultrahigh risk for psychosis. Acta Psychiatrica Scandinavica, 2017, 135, 250-258.	4.5	25
9	White matter maturation during 12 months in individuals at ultra‐high‐risk for psychosis. Acta Psychiatrica Scandinavica, 2018, 137, 65-78.	4.5	23
10	Cognitive remediation plus standard treatment versus standard treatment alone for individuals at ultra-high risk of developing psychosis: Results of the FOCUS randomised clinical trial. Schizophrenia Research, 2020, 224, 151-158.	2.0	23
11	Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultra‐high risk for psychosis. Human Brain Mapping, 2019, 40, 5185-5201.	3.6	22
12	Experiential negative symptoms are more predictive of real-life functional outcome than expressive negative symptoms in clinical high-risk states. Schizophrenia Research, 2020, 218, 151-156.	2.0	19
13	Effectiveness of cognitive remediation in the ultra‐high risk state for psychosis. World Psychiatry, 2020, 19, 401-402.	10.4	18
14	Course of illness in a sample of patients diagnosed with a schizotypal disorder and treated in a specialized early intervention setting. Findings from the 3.5 year follow-up of the OPUS II study. Schizophrenia Research, 2017, 182, 24-30.	2.0	16
15	Non-pharmacological modulation of cerebral white matter organization: A systematic review of non-psychiatric and psychiatric studies. Neuroscience and Biobehavioral Reviews, 2018, 88, 84-97.	6.1	13
16	Emotion recognition latency, but not accuracy, relates to real life functioning in individuals at ultra-high risk for psychosis. Schizophrenia Research, 2019, 210, 197-202.	2.0	13
17	Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 569-579.	1.5	12
18	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. Schizophrenia Bulletin, 2021, 47, 1018-1028.	4.3	10

#	Article	IF	Citations
19	No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosisâ€"A Randomized Clinical Trial. Frontiers in Psychiatry, 2020, 11, 873.	2.6	9
20	Global fractional anisotropy predicts transition to psychosis after 12 months in individuals at ultraâ€high risk for psychosis. Acta Psychiatrica Scandinavica, 2021, 144, 448-463.	4.5	9
21	Predictors of remission from the ultraâ€high risk state for psychosis. Microbial Biotechnology, 2021, 15, 104-112.	1.7	8
22	Assessing social skills in individuals at ultra-high risk for psychosis: Validation of the High Risk Social Challenge task (HiSoC). Schizophrenia Research, 2020, 215, 365-370.	2.0	7
23	Basic symptoms influence realâ€life functioning and symptoms in individuals at high risk for psychosis. Acta Psychiatrica Scandinavica, 2020, 141, 231-240.	4.5	7
24	Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months. European Psychiatry, 2020, 63, e83.	0.2	7
25	Changes in negative symptoms are linked to white matter changes in superior longitudinal fasciculus in individuals at ultra-high risk for psychosis. Schizophrenia Research, 2021, 237, 192-201.	2.0	6
26	Examining speed of processing of facial emotion recognition in individuals at ultra-high risk for psychosis: Associations with symptoms and cognition. Schizophrenia Research, 2018, 195, 562-563.	2.0	5
27	Validation of the MUSIC Model of Motivation Inventory for use with cognitive training for schizophrenia spectrum disorders: A multinational study. Schizophrenia Research, 2019, 206, 142-148.	2.0	5
28	Investigating Cognitive and Clinical Predictors of Real-Life Functioning, Functional Capacity, and Quality of Life in Individuals at Ultra-High Risk for Psychosis. Schizophrenia Bulletin Open, 2020, 1, .	1.7	5
29	Self-perceived cognitive impairments in psychosis ultra-high risk individuals: associations with objective cognitive deficits and functioning. NPJ Schizophrenia, 2020, 6, 31.	3.6	5
30	Supplementary data for a focused review and meta-analysis of 1H-MRS studies on cerebral glutamate and GABA levels in high-risk of psychosis states. Data in Brief, 2020, 28, 104920.	1.0	1
31	Development of Executive Functions as Reflected in Daily Life Behaviors in Young Adults at Ultra-High Risk for Psychosis: Associations With Symptoms and Functioning. Schizophrenia Bulletin Open, 2020, 1, .	1.7	1